Watchlist

Watchlist
Alimera Sciences, Inc. (ALIM)
Alimera Sciences, Inc. (ALIM)
Healthcare events next week
Upcoming events in healthcare next week: More news on: Zogenix, Inc., Omnicell, Inc., Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more …
Alimera Sciences' (ALIM) CEO Dan Myers on Q3 2017 Results - Earnings Call Transcript
Alimera Sciences Inc. (ALIM) Q3 2017 Results Earnings Conference Call November 2, 2017, 09:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - CEO Rick Eiswirth - President and CFO Analysts Francois Brisebois - Laidlaw & Company Yi Chen - HC Wainwright Pr…
CMS issues final list of therapies facing expiration of pass-through status for 2018
The Centers for Medicare & Medicaid Services (CMS) has issued its final update on the therapies facing expiration of pass-through status in 2018. More news on: Omeros Corporation, Eli Lilly and Company, Astellas Pharma, Inc. ADR, Healthcare stocks news, Read more …
Alimera Sciences, Inc. 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2017 Q3 earnings Read more …
Alimera Sciences misses by $0.03, misses on revenue
Alimera Sciences (NASDAQ: ALIM ): Q3 EPS of -$0.08 misses by $0.03 . Revenue of $9.8M (+18.1% Y/Y) misses by $0.88M . Press Release More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Notable earnings after Wednesday's close
AAC , ACXM , ADSW , AEGN , ALIM , ALL , ANSS , AR , ARC , AREX , ARI , ARRS , ATRC , AWK , AXGN , BBRG , BFAM , BGC , BLDP , BOJA , BXP , CACI , CAKE , CAVM , CBPO , CCRN , CF , CFMS , CHDN , CLVS , CMPR , CNAT , CSGS , CSU , CTRP , CWST , CYH , CZR , …
Alimera Sciences' (ALIM) CEO Dan Myers on Q2 2017 Results - Earnings Call Transcript
Alimera Sciences Inc. (ALIM) Q2 2017 Earnings Conference Call August 03, 2017 9:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts Francois Brisebois - Laidlaw & Company …
Alimera Sciences beats by $0.01, misses on revenue
Alimera Sciences (NASDAQ: ALIM ): Q2 EPS of -$0.04 beats by $0.01 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
Notable earnings after Wednesday's close
AAC , ADSW , AEL , AGO , AIG , ALEX , ALIM , ANSS , APTI , APU , AR , AREX , ARRS , ATO , AVB , AWK , AWR , AXGN , AYX , BECN , BGC , BIVV , BKCC , BLDP , BMRN , BREW , BRKS , CA , CAKE , CATM , CAVM , CBPO , CC , CCRN , CENT , CENX , CF , CIM , CINF ,…
pSivida amends agreement with Alimera, grants EMEA rights to Durasert, new indication for Iluvien planned; shares ahead 2% after hours
Nano cap pSivida (NASDAQ: PSDV ) is up 2% after hours on average volume on the heels of its announcement that it has amended its license and collaboration agreement with Alimera Sciences (NASDAQ: ALIM ). More news on: pSivida Corp., Alimera Sciences, Inc., Healthcare stocks n…
Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2017 Results - Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) Q1 2017 Earnings Conference Call May 09, 2017 08:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - Chief Financial Officer Dr. Christopher Riemann - Board of Directors of Cincinnati Eye Institute …
Alimera Sciences, Inc. (ALIM)